Volume | 1,017,281 |
|
|||||
News | - | ||||||
Day High | 14.84 | Low High |
|||||
Day Low | 12.945 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Nurix Therapeutics Inc | NRIX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
14.33 | 12.945 | 14.84 | 13.59 | 14.44 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
13,876 | 1,017,281 | $ 13.65 | $ 13,887,713 | - | 4.22 - 18.12 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:59:36 | 1 | $ 13.51 | USD |
Nurix Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
664.47M | 48.89M | - | 76.99M | -143.95M | -2.94 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Nurix Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NRIX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 16.45 | 16.81 | 12.945 | 15.46 | 2,237,590 | -2.86 | -17.39% |
1 Month | 13.09 | 18.12 | 12.55 | 15.29 | 1,386,823 | 0.50 | 3.82% |
3 Months | 8.19 | 18.12 | 7.65 | 13.27 | 1,028,289 | 5.40 | 65.93% |
6 Months | 5.24 | 18.12 | 4.22 | 10.72 | 886,982 | 8.35 | 159.35% |
1 Year | 11.56 | 18.12 | 4.22 | 10.28 | 608,044 | 2.03 | 17.56% |
3 Years | 28.76 | 37.425 | 4.22 | 15.12 | 477,301 | -15.17 | -52.75% |
5 Years | 20.25 | 52.38 | 4.22 | 17.65 | 444,329 | -6.66 | -32.89% |
Nurix Therapeutics Description
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications. |